AXTI Eyes Record InP Quarter Amid AI Demand, but Permit Overhang Remains

What happened

AXT could post its biggest-ever Indium Phosphide quarter in Q2 2026, driven by surging AI demand and a record backlog that boosts revenue visibility. However, the company's own filings state that export permit timing remains non-forecastable and it cannot estimate when U.S. shipments will resume, with North America revenue still negligible at $0.207M in Q1'26. The DeepValue report rates the stock a POTENTIAL SELL at $92.40, arguing that the market is pricing in scalable AI-optics monetization that hinges on an exogenous gating factor beyond management's control. While the news reinforces the demand narrative, the fundamental constraint—China's export licensing for InP substrates—has not been resolved, leaving revenue conversion uncertain. Investors should watch for measurable permit cadence disclosure and a sustained inflection in North America revenue before assuming the bull case materializes.

Implication

The news of a potential record InP quarter supports the bullish case, but the DeepValue analysis highlights that the stock already embeds high expectations. Until filings replace 'cannot predict' language with quantified permit cycle times and North America revenue rises materially from near-zero, the risk/reward skews negative. Trimming into strength or waiting for a lower entry near $60 is prudent. Any positive surprise in permit disclosure could trigger a re-rating, but that is not yet evident.

Thesis delta

The news does not change the fundamental thesis that AXT's valuation depends on export permit predictability and U.S. revenue recovery. The Zacks article reinforces the demand side, but the core risk—unforecastable permit timing—remains unchanged. The thesis delta is neutral; the need for observable permit cadence and North America revenue inflection remains the key to unlocking value.